SMAD2/3 Recombinant Rabbit mAb (S-5467)

SMAD2 and SMAD3 are two highly homologous and functionally closely related mediator signal transduction proteins in the TGF-β signaling pathway. Structurally, they both consist of an MH1 (MAD homology 1) domain, an MH2 domain, and a linker region in between, with the MH1 domain responsible for sequence-specific DNA binding and nuclear localization, while the MH2 domain mediates interactions with various proteins including receptors, SMAD4, and transcriptional cofactors. In the canonical signaling pathway, upon TGF-β ligand binding to its receptor, the receptor-regulated SMADs (R-SMADs), namely SMAD2 and SMAD3, are phosphorylated and activated, forming heterotrimeric complexes with the common SMAD4 and translocating into the nucleus. Once in the nucleus, these complexes bind to SMAD-binding elements on DNA and, in coordination with numerous transcriptional coactivators or corepressors, initiate or repress the expression of specific target genes, thereby regulating a broad spectrum of biological processes including cell proliferation, differentiation, apoptosis, migration, and extracellular matrix remodeling. Although SMAD2 and SMAD3 belong to the same R-SMAD family, they exhibit significant functional differences: SMAD3 can bind DNA directly, whereas SMAD2 requires cooperation with SMAD4 or other cofactors to stably associate with DNA; moreover, SMAD3 plays a more prominent role in inducing apoptosis and inhibiting cell growth, while SMAD2 is more focused on regulating embryonic stem cell fate. Dysregulation of these two signaling pathways is associated with various diseases, where their functional abnormalities can promote tissue fibrosis and malignant tumor progression through overactivation, or lead to developmental defects and immune dysregulation through loss of function.